Sun Pharmaceutical signs agreement with Samsung BioLogics for psoriasis drug

The novel drug known as Tildrakizumab is currently under review by the US FDA and the European Medicines Agency (EMA). The value of the contract is about $55.5 million.

Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.